RPE based gene and cell therapy for inherited retinal diseases: A review

被引:6
作者
Sanie-Jahromi, Fatemeh [1 ]
Nowroozzadeh, M. Hossein [1 ]
机构
[1] Shiraz Univ Med Sci, Poostchi Ophthalmol Res Ctr, Sch Med, Dept Ophthalmol, Shiraz, Iran
关键词
RPE; Gene therapy; Cell therapy; IRD; LEBER CONGENITAL AMAUROSIS; OCULAR SUBRETINAL INJECTION; PIGMENT EPITHELIAL-CELLS; ADENOASSOCIATED VIRUS; VORETIGENE NEPARVOVEC; MACULAR DEGENERATION; VISUAL FUNCTION; MOUSE MODEL; STEM-CELLS; MUTATIONS;
D O I
10.1016/j.exer.2022.108961
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The Retinal Pigment Epithelium (RPE) is the supportive layer located beneath the neural retina. Its health is essential for the proper function of photoreceptors. Indeed, any condition involving the RPE has the potential to induce an antegrade degeneration of the photoreceptors and inner retinal layers. Traditionally, degenerative disorders of the neural retina have been considered untreatable. However, the advent of gene and cell replacement therapies brings hope to halt or even cure retinal degenerative diseases. This study aims to review the most recent clinical trials registered on the RPE-based gene/cell intervention for the treatment of inherited retinal diseases (IRD). In this review, we provided an update on the clinical studies on the RPE-based gene/cell therapy for the treatment of IRD, summarized recent studies in this regard, and present the results of the cor-responding clinical trials. A brief description of the details applied in the techniques, the advantages and withdraws of the utilized strategies were also included. This study provided evidence to show that gene therapy and cell replacement therapy have a great potential to become a successful treatment for IRD in the following decades, however, future studies should focus on novel methods to increase the safety and efficacy of the treatment.
引用
收藏
页数:10
相关论文
共 98 条
[91]   Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy [J].
Weleber, Richard G. ;
Pennesi, Mark E. ;
Wilson, David J. ;
Kaushal, Shalesh ;
Erker, Laura R. ;
Jensen, Lauren ;
McBride, Maureen T. ;
Flotte, Terence R. ;
Humphries, Margaret ;
Calcedo, Roberto ;
Hauswirth, William W. ;
Chulay, Jeffrey D. ;
Stout, J. Timothy .
OPHTHALMOLOGY, 2016, 123 (07) :1606-1620
[92]  
Whalen R.G., 1994, GENE THERAPEUTICS, P60
[93]   Bestrophins and retinopathies [J].
Xiao, Qinghuan ;
Hartzell, H. Criss ;
Yu, Kuai .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2010, 460 (02) :559-569
[94]  
Yu J., 2018, INVESTIG OPHTHALMOL, V59, P2468
[95]   Age-Related Macular Degeneration (AMD) Transmitochondrial Cybrids Protected from Cellular Damage and Death by Human Retinal Progenitor Cells (hRPCs) [J].
Yu, Jeffrey J. ;
Azzam, Daniel B. ;
Chwa, Marilyn ;
Schneider, Kevin ;
Cho, Jang-Hyeon ;
Hsiang, Chinhui ;
Klassen, Henry ;
Kenney, M. Cristina ;
Yang, Jing .
STEM CELLS INTERNATIONAL, 2021, 2021
[96]  
Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
[97]   Suppression of Ca2+ signaling in a mouse model of Best disease [J].
Zhang, Youwen ;
Stanton, J. Brett ;
Wu, Jiang ;
Yu, Kuai ;
Hartzell, H. Criss ;
Peachey, Neal S. ;
Marmorstein, Lihua Y. ;
Marmorstein, Alan D. .
HUMAN MOLECULAR GENETICS, 2010, 19 (06) :1108-1118
[98]   Personalized therapeutic strategies for patients with retinitis pigmentosa [J].
Zheng, Andrew ;
Li, Yao ;
Tsang, Stephen H. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (03) :391-402